Navigation Links
ULURU Inc. Reports First Quarter 2008 Financial Results
Date:5/12/2008

containing product which will enable us to compete in this growing segment of the market."

About ULURU Inc.:

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing our innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to future financial performance of ULURU Inc. (the "Company"), the expected launch of our wound dressing product, development of a silver containing product, impact on cost of the production scale-up, the launch of additional products, and our expectation that our licensing fees will increase and offset increased expenses. When used in this press release, the words "may," "targets," "goal," "could," "should," "would," "believe," "feel," "expects," "confident," "anticipate," "estimate," "intend," "plan," "potential" and similar expressions may be indicative of forward-looking statements including without limitation statements relating to the progress of our technology, pre-clinical results for our products and advantages of our products. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurre
'/>"/>

SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
2. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
4. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. Reports Third Quarter 2007 Results
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
8. ULURU Inc. Announces Odd-Lot Buy Back Offer
9. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
10. Novadaq Reports Financial Results for the First Quarter of 2008
11. Isis Reports Financial Results and Highlights for First Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...eClaim Revenue Gateway Alleviates Insurance Claim ...roviders , , ATLANTA, Dec. 2 /PRNewswire-Fi...day announced a new healthcare receivables solutio...s well as hospitals. SunTrust eClaim Revenue Gatew...issions as well as payment collection and processi...
(Date:12/2/2008)...o., Dec. 2 MicroPhage, Inc., htt... M. Taussig, MD has joined,the company,s Board of...onal,Jewish Medical and Research Center in Denver...espiratory diseases, from 1993 to 2006. His medic...I have followed MicroPhage extensively and am impr...
(Date:12/2/2008)...s Missing Opportunities to Connect - , , - ...escription Drug Abuse Dangers - , , NEW YOR...Partnership for a Drug-Free America and MetLife Fo...ail or text messaging to communicate with their t...nect with their kids about drug and alcohol use. T...
(Date:12/2/2008)...OCKVILLE, Md., Dec. 2 F...iods and increased supervision of work hour limits...nment, according to a new Institute of Medicine re... and Quality. , , The report is the result...ewed the relationship between residents, work sche...
Breaking Medicine News(10 mins):Health News:Healthcare Providers Now Able to Perform Real-Time Patient Eligibility Verification 2Health News:Healthcare Providers Now Able to Perform Real-Time Patient Eligibility Verification 3Health News:Healthcare Providers Now Able to Perform Real-Time Patient Eligibility Verification 4Health News:MicroPhage Selects Lynn Taussig, MD for Board of Directors 2Health News:Bridging the Technology Gap: Study Confirms Teens Open to Discussing Drugs and Alcohol With Parents By Email, Cell Phones 2Health News:Bridging the Technology Gap: Study Confirms Teens Open to Discussing Drugs and Alcohol With Parents By Email, Cell Phones 3Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 2Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 3Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 4
...n with prostate cancer who receive a common medica...uce // the risk of recurrence after surgery may be...he research showed men treated with androgen depri...er run a higher risk of developing the bone-thinni...
... might benefit from the implantation of cardiac pa...t the conclusion // after studying 20 patients wit...currence of interrupted heart rhythm during seizur...ring seizures might be responsible for the higher ...
...e drug rolipram in mice shows promise for possible...say researchers according to a new study. Alzheime... the elderly with typical symptoms being memory lo... changes. The main factor in the cause of AD is th...
...vaginal birth after first delivering a child via c...r newborns at risk,// say researchers based on fin... anything will go wrong is extremely small, uterin...n due to lack of oxygen (hypoxic-ischemic encephal...
Other Medicine News:
(Date:12/1/2008)...ARD, Denmark, December 1 ...with the intent to procure an MVA-based,third ge...ment Services,Canada, on behalf of the Canadian D...ract to Bavarian Nordic for the delivery of IMVAMU... use IMVAMUNE(R) as part of the,country,s bio-pre...
(Date:11/30/2008)...ec. 1 Abnormalities in ...in children with autism spectrum disorder by using...y presented today at the annual meeting of the Rad..., "Using MEG, we can record the tiny magnetic fi...aid Timothy Roberts, Ph.D., vice chair of research...
(Date:11/26/2008)...information density, automation and intelligent cl...trasound to an all new level , , CHICAGO, I...Healthcare ( www.siemens.com/healthcare ) highli...Scanner (ABVS)(1), the world,s first multi-use, a...4th Scientific Assembly and Annual Meeting of the ...
(Date:11/25/2008)...FRANCISCO, Calif., Nov. 25 Proteol...nt of novel therapeutics that target,protein degr..., today,announced that data from two ongoing Phas...eloma will be presented at the upcoming 50th Annua...ASH). Carfilzomib is the first in a new class,of...
Breaking Medicine Technology:The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Ohio Company to Debut Turnkey Marketing Material During Florida National Dental Convention 20824 1Ohio Company to Debut Turnkey Marketing Material During Florida National Dental Convention 20824 2Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen Deprivation Therapy 2287 1Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen Deprivation Therapy 2287 2Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen Deprivation Therapy 2287 3Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen Deprivation Therapy 2287 4Bamboo instant houses will soon shelter Sichuan quake victims 3504 1Bamboo instant houses will soon shelter Sichuan quake victims 3504 2Is tap water safe for expectant mothers 3F 20821 1Is tap water safe for expectant mothers 3F 20821 2
...therapeutic approach for the treatment,of early an... 2007 /PRNewswire-FirstCall/ - AEterna,Zentaris In...,focused on endocrine therapy and oncology, today ...ts growth hormone-releasing,hormone (GHRH) antagon...ciation for Cancer Research (AACR) Annual Meeting ...
...pr 16, 2007 - Arsenic, a naturally,occurring eleme...r,2,000 years, and even now remains a venerable co..., Today, due in measure to the efforts of investig...ancer Research Foundation,s,(SWCRF) "Institute Wit...ed in therapy for the treatment of certain types o...
Other Medicine Technology:AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells 2Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells 3
For determination of HDL-cholesterol in serum and plasma. For Hitachi 717. Specific immunochemical inhibition of non-HDL-lipoproteins. Excellent correlation with established reference methods. Endpoi
Cholesterol/HDL Standard 50 mg/dl.
Intended for the in vitro precipitation of very low density and low density lipoproteins in serum or plasma. Single vial, dry powder precipitating reagent. Total cholesterol reagent not included.
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L
Medicine Products: